• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠1型和2型类固醇5α-还原酶的药代动力学参数及抑制机制:GI198745和非那雄胺在大鼠体内不同活性的决定因素

Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.

作者信息

Stuart J D, Lee F W, Simpson Noel D, Kadwell S H, Overton L K, Hoffman C R, Kost T A, Tippin T K, Yeager R L, Batchelor K W, Bramson H N

机构信息

Division of Biochemistry, Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA.

出版信息

Biochem Pharmacol. 2001 Oct 1;62(7):933-42. doi: 10.1016/s0006-2952(01)00728-6.

DOI:10.1016/s0006-2952(01)00728-6
PMID:11543729
Abstract

The interaction of baculovirus expressed rat steroid 5alpha-reductase types 1 and 2 (r5AR1 and r5AR2) with 17beta-N-(2,5-bis(trifluoromethyl)phenyl)carbamoyl-4-aza-5alpha-androst-1-en-3-one (GI198745) was investigated at pH 7 and 37 degrees. This 5alpha-reductase inhibitor was found previously to be a time-dependent inhibitor of the two human 5alpha-reductase isozymes. In contrast, we demonstrate in the present study that although GI198745 is a potent time-dependent inhibitor of r5AR2, it is a classical rapid-equilibrium inhibitor of r5AR1. This type of behavior with human and rat 5alpha-reductases has been shown for the inhibitor 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one (finasteride), a current therapy for benign prostatic hyperplasia. Inhibition of r5AR1 by GI198745 was competitive with testosterone and followed Michaelis-Menten kinetics with a K(i) value of 0.3 +/- 0.02 nM. Data for the inhibition of r5AR2 by GI198745 were consistent with a two-step mechanism, where K(i) is the dissociation constant for an initial enzyme-inhibitor complex and k(3) is the rate constant for the second slow step. The pseudo-bimolecular rate constant (k(3)/K(i)) for the association of GI198745 with r5AR2 was (2.0 +/- 0.4) x 10(7) M(-1) sec(-1). The high affinity of this inhibitor for r5AR2 was further demonstrated by the inability of the enzyme-inhibitor complex to dissociate after approximately 7 days of dialysis at 4 degrees. Both GI198745 and finasteride appear to inactivate r5AR2 by apparent irreversible modification, but are classical, reversible inhibitors of r5AR1. Therefore, we hypothesize that because of its pharmacokinetic parameters and increased potency against r5AR1, GI198745 is more effective than finasteride in preventing the growth of the rat prostate.

摘要

在pH 7和37摄氏度条件下,研究了杆状病毒表达的大鼠1型和2型类固醇5α-还原酶(r5AR1和r5AR2)与17β-N-(2,5-双(三氟甲基)苯基)氨基甲酰基-4-氮杂-5α-雄甾-1-烯-3-酮(GI198745)的相互作用。先前发现这种5α-还原酶抑制剂是两种人类5α-还原酶同工酶的时间依赖性抑制剂。相比之下,我们在本研究中证明,虽然GI198745是r5AR2的有效时间依赖性抑制剂,但它是r5AR1的经典快速平衡抑制剂。抑制剂17β-(N-叔丁基氨基甲酰基)-4-氮杂-5α-雄甾-1-烯-3-酮(非那雄胺),一种目前用于治疗良性前列腺增生的药物,已显示出对人和大鼠5α-还原酶具有这种行为类型。GI198745对r5AR1的抑制作用与睾酮具有竞争性,并遵循米氏动力学,K(i)值为0.3±0.02 nM。GI198745对r5AR2抑制作用的数据与两步机制一致,其中K(i)是初始酶-抑制剂复合物的解离常数,k(3)是第二个慢步骤的速率常数。GI198745与r5AR2结合的伪二级速率常数(k(3)/K(i))为(2.0±0.4)×10(7) M(-1) sec(-1)。在4摄氏度下透析约7天后,酶-抑制剂复合物无法解离,进一步证明了该抑制剂对r5AR2的高亲和力。GI198745和非那雄胺似乎都通过明显的不可逆修饰使r5AR2失活,但它们是r5AR1的经典可逆抑制剂。因此,我们假设由于其药代动力学参数以及对r5AR1增强的效力,GI198745在预防大鼠前列腺生长方面比非那雄胺更有效。

相似文献

1
Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.大鼠1型和2型类固醇5α-还原酶的药代动力学参数及抑制机制:GI198745和非那雄胺在大鼠体内不同活性的决定因素
Biochem Pharmacol. 2001 Oct 1;62(7):933-42. doi: 10.1016/s0006-2952(01)00728-6.
2
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.在不可逆5α-还原酶抑制剂GI198745和非那雄胺存在的情况下二氢睾酮周转的模型。
Clin Pharmacol Ther. 1998 Dec;64(6):636-47. doi: 10.1016/S0009-9236(98)90054-6.
3
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.双氢睾酮与人类良性前列腺增生中5α-还原酶抑制的概念。
World J Urol. 2002 Apr;19(6):413-25. doi: 10.1007/s00345-002-0248-5.
4
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.双氢睾酮与人类良性前列腺增生中5α-还原酶抑制的概念
Eur Urol. 2000 Apr;37(4):367-80. doi: 10.1159/000020181.
5
Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.
Biochemistry. 1996 Mar 19;35(11):3457-64. doi: 10.1021/bi952472+.
6
Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition.
J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):55-64. doi: 10.1016/s0960-0760(97)00002-2.
7
Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.人成骨样细胞主要表达1型类固醇5α-还原酶。
J Clin Endocrinol Metab. 2002 Dec;87(12):5401-7. doi: 10.1210/jc.2001-011902.
8
Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.液相色谱串联质谱法同时对5α-还原酶抑制剂和雄激素进行药代动力学和药效学分析。
Talanta. 2015 Jan;131:728-35. doi: 10.1016/j.talanta.2014.07.087. Epub 2014 Aug 14.
9
Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
Biochemistry. 1995 Oct 17;34(41):13453-9. doi: 10.1021/bi00041a024.
10
Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids.δ1-4-氮杂甾体对甾体5α-还原酶时间依赖性抑制的配体结合能与活化能之间的线性关系。
J Biol Chem. 2001 Jun 15;276(24):21359-64. doi: 10.1074/jbc.M100793200. Epub 2001 Mar 8.

引用本文的文献

1
Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review.当前对前列腺炎中雄激素信号及其治疗的理解:综述。
Curr Med Chem. 2024;31(27):4249-4266. doi: 10.2174/0109298673279207231228070533.
2
Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.雄激素依赖性疾病药物设计与药物发现的最新进展
Curr Med Chem. 2016;23(8):792-815. doi: 10.2174/0929867323666160210125642.
3
A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.
多尺度、机制驱动的 5α-还原酶抑制对前列腺维持作用的动态模型。
PLoS One. 2012;7(9):e44359. doi: 10.1371/journal.pone.0044359. Epub 2012 Sep 6.
4
Targeting 5α-reductase for prostate cancer prevention and treatment.针对 5α-还原酶预防和治疗前列腺癌。
Nat Rev Urol. 2011 May 31;8(7):378-84. doi: 10.1038/nrurol.2011.67.
5
The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men.注射睾酮剂量和年龄对年轻和老年男性睾酮向雌二醇和二氢睾酮转化的影响。
J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64. doi: 10.1210/jc.2010-0102. Epub 2010 Jun 9.
6
Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice.非那雄胺对C57BL/6J和DBA/2J小鼠急性乙醇戒断严重程度影响的性别差异。
Neuroscience. 2007 May 25;146(3):1302-15. doi: 10.1016/j.neuroscience.2007.02.051. Epub 2007 Apr 11.
7
A new look at the 5alpha-reductase inhibitor finasteride.对5α-还原酶抑制剂非那雄胺的新审视。
CNS Drug Rev. 2006 Spring;12(1):53-76. doi: 10.1111/j.1527-3458.2006.00053.x.